Medical Internal Radiation Dose (MIRD) Committee

Develop and provide a standardized framework and methodology for calculation of internal dose quantities in nuclear medicine.
Compile, evaluate and disseminate data needed to implement standardized internal dosimetry methods including radionuclide decay properties and emissions, energy absorbed fractions and anatomic models.
Collect and assess experimental and peer-reviewed data to publish dose estimate reports for selected new radiopharmaceuticals which significantly impact the current practice of nuclear medicine.
Provide peer-reviewed evaluations of proposed new dosimetry models and methods including correlating dose with biological response for cellular, animal and clinical trials data.
Address other critical and timely dosimetry issues that may impact the current practice of nuclear medicine.
Develop, test and publish software and internet tools that implement MIRD calculation models and techniques including dose-response data and biological effective or equivalent dose quantities.
Actively work with other national and international committees through joint meetings and symposia to establish uniformity in dosimetry models, techniques, named special quantities and units of dose and biological response.

Recent Key Accomplishments:

MIRD Pamphlet No. 22: Radiobiology and Dosimetry of Alpha-Particle Emitters for Targeted Radionuclide Therapy.
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature.
MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for ¹¹¹In- and ⁹⁰Y-Ibritumomab Tiuxetan.
MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy.